Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against ...
Nisa Investment Advisors LLC Purchases 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...
Hold Rating Maintained Amidst Revance Therapeutics Acquisition Uncertainty
Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17.Invest with Confidence: ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
Zacks.com on MSN6h
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...
Should You Be Impressed By Progress Software Corporation's (NASDAQ:PRGS) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...